Jefferies Adjusts Astellas Pharma's Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy
MT NewswiresDec 18, 2023 05:12 ET
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen
MT NewswiresOct 24, 2023 05:23 ET
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy
MT NewswiresMay 2, 2023 06:14 ET
Taysha Downgraded at Jefferies Citing Uncertain Outlook for Lead Asset
Seeking AlphaFeb 1, 2023 13:03 ET
Taysha Gene Therapies Downgraded to Neutral at Goldman Sachs on Measured Outlook
Seeking AlphaNov 9, 2022 11:57 ET
No Data
No Data